290 related articles for article (PubMed ID: 34164549)
1. Molecular landscape of head and neck cancer and implications for therapy.
Farah CS
Ann Transl Med; 2021 May; 9(10):915. PubMed ID: 34164549
[TBL] [Abstract][Full Text] [Related]
2. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
3. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
4. Genomic insights into head and neck cancer.
Beck TN; Golemis EA
Cancers Head Neck; 2016; 1():. PubMed ID: 29034103
[TBL] [Abstract][Full Text] [Related]
5. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.
Harbison RA; Kubik M; Konnick EQ; Zhang Q; Lee SG; Park H; Zhang J; Carlson CS; Chen C; Schwartz SM; Rodriguez CP; Duvvuri U; Méndez E
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046007
[TBL] [Abstract][Full Text] [Related]
8. Head and neck cancer: Current challenges and future perspectives.
Bhat GR; Hyole RG; Li J
Adv Cancer Res; 2021; 152():67-102. PubMed ID: 34353444
[TBL] [Abstract][Full Text] [Related]
9. Immune landscape in molecular subtypes of human papillomavirus-negative head and neck cancer.
Xie M; Chaudhary R; Slebos RJC; Lee K; Song F; Poole MI; Hoening DS; Noel LC; Hernandez-Prera JC; Conejo-Garcia JR; Chung CH; Tan AC
Mol Carcinog; 2024 Jan; 63(1):120-135. PubMed ID: 37750589
[TBL] [Abstract][Full Text] [Related]
10. Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival.
Li H; Torabi SJ; Yarbrough WG; Mehra S; Osborn HA; Judson B
JAMA Otolaryngol Head Neck Surg; 2018 Jun; 144(6):519-525. PubMed ID: 29801040
[TBL] [Abstract][Full Text] [Related]
11. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.
Braakhuis BJ; Snijders PJ; Keune WJ; Meijer CJ; Ruijter-Schippers HJ; Leemans CR; Brakenhoff RH
J Natl Cancer Inst; 2004 Jul; 96(13):998-1006. PubMed ID: 15240783
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus status and p16(INK4A) expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia.
Antonsson A; Neale RE; Boros S; Lampe G; Coman WB; Pryor DI; Porceddu SV; Whiteman DC
Cancer Epidemiol; 2015 Apr; 39(2):174-81. PubMed ID: 25677091
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.
Lechner M; Frampton GM; Fenton T; Feber A; Palmer G; Jay A; Pillay N; Forster M; Cronin MT; Lipson D; Miller VA; Brennan TA; Henderson S; Vaz F; O'Flynn P; Kalavrezos N; Yelensky R; Beck S; Stephens PJ; Boshoff C
Genome Med; 2013; 5(5):49. PubMed ID: 23718828
[TBL] [Abstract][Full Text] [Related]
14. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles in HPV-infected head and neck cancer.
Schlecht NF; Burk RD; Adrien L; Dunne A; Kawachi N; Sarta C; Chen Q; Brandwein-Gensler M; Prystowsky MB; Childs G; Smith RV; Belbin TJ
J Pathol; 2007 Nov; 213(3):283-93. PubMed ID: 17893858
[TBL] [Abstract][Full Text] [Related]
16. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
17. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
Keck MK; Zuo Z; Khattri A; Stricker TP; Brown CD; Imanguli M; Rieke D; Endhardt K; Fang P; Brägelmann J; DeBoer R; El-Dinali M; Aktolga S; Lei Z; Tan P; Rozen SG; Salgia R; Weichselbaum RR; Lingen MW; Story MD; Ang KK; Cohen EE; White KP; Vokes EE; Seiwert TY
Clin Cancer Res; 2015 Feb; 21(4):870-81. PubMed ID: 25492084
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J; Pérez-García J; Seijas-Tamayo R; Mesía R; Rubió-Casadevall J; García-Girón C; Iglesias L; Carral Maseda A; Adansa Klain JC; Taberna M; Vazquez S; Gómez MA; Del Barco E; Ocana A; González-Sarmiento R; Cruz-Hernández JJ
Sci Rep; 2020 Oct; 10(1):16634. PubMed ID: 33024167
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
